# A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

> **NCT00349596** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT00349596
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00349596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00349596, "A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00349596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*